Depressive Disorder News and Research

RSS

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

Two Boston University School of Medicine faculty members, Pietro Cottone, PhD, an assistant professor of pharmacology and psychiatry and Michael Silverstein, MD, an associate professor of pediatrics, were each awarded the prestigious National Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientisits grant with ten other investigators from around the country.

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

5 Feb 2011

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

24 Jan 2011

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm Inc. today announced that Health Canada's Therapeutic Products Directorate (TPD) has approved OLEPTRO, a novel once-daily formulation of the antidepressant trazodone, for the symptomatic relief of Major Depressive Disorder in adults.

21 Jan 2011

Preliminary top-line results from levomilnacipran Phase III study for MDD

Forest Laboratories, and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of major depressive disorder.

20 Jan 2011

Study elaborates relationship between obesity and MDD-R, long-term use of ADs

This study demonstrates that patients using antidepressants continuously, mostly serotonin-selective reuptake inhibitors, show significantly more overweight and obesity than those using them intermittently or not at all.

18 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Researchers present new findings on role of relationship between patient and therapist

This study published in the last 2010 issue of Psychotherapy and Psychosomatics suggests that therapist and patient ratings of therapeutic alliance predict therapeutic progress.

18 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

Stigma remains over Major Depressive Disorder

Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor.

11 Jan 2011

Bright light therapy for the aged depressed: Study

A new study shows that exposure to bright light may ease symptoms of depression in elderly people. The researchers tried three weeks of bright light therapy using specially designed light boxes and saw that it improved symptoms of depression by as much as 54% in older adults with depression. The light therapy also improved sleep and optimized levels of the neurotransmitter serotonin. Low levels of serotonin are associated with depression and often targeted by antidepressant drugs. This is the first study of its kind to show a beneficial effect of bright light therapy on treating depression in the elderly with non-seasonal major depressive disorder.

5 Jan 2011

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Clinical Data, Inc. today announced that the Company has closed the sale of its genetic and pharmacogenomic testing and biomarker development business to Transgenomic, Inc. for $15.5 million. The sale completes Clinical Data's transformation into a pharmaceutical company with a deep product pipeline, including two promising late-stage compounds, the most advanced of which is vilazodone, a new treatment in development for Major Depressive Disorder.

30 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Psychotic depression: the reason for treatment failure with antidepressants

A new study shows that patients with depression who also have psychotic-like symptoms, feelings of being persecuted, or believing others are plotting against them or hearing voices are less likely to respond to antidepressants. The study also showed that bipolar disorder does not appear to be associated with treatment resistance in patients with depression as believed earlier.

7 Dec 2010

Study finds duplicated region of DNA in major depressive disorder

A large genetic study of people with major depression has found that a duplicated region of DNA on chromosome 5 predisposes people to the disorder. The gene involved plays an important role in the development of nerve cells, adding to evidence that disruptions in neurotransmission networks form a biological basis for depression.

1 Dec 2010

Use of aspirin and statins can reduce depression: Study

A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.

25 Nov 2010

Depressive Disorder News and Research

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

FDA approves Clinical Data's Viibryd for major depressive disorder

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Preliminary top-line results from levomilnacipran Phase III study for MDD

Study elaborates relationship between obesity and MDD-R, long-term use of ADs

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Researchers present new findings on role of relationship between patient and therapist

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

Stigma remains over Major Depressive Disorder

Bright light therapy for the aged depressed: Study

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Psychotic depression: the reason for treatment failure with antidepressants

Study finds duplicated region of DNA in major depressive disorder

Use of aspirin and statins can reduce depression: Study

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News